Antimalarial efficacy of MMV390048, an inhibitor of Plasmodium phosphatidylinositol 4-kinase.

Paquet, TORCID logo; Le Manach, C; Cabrera, DG; Younis, Y; Henrich, PP; Abraham, TSORCID logo; Lee, MC; Basak, RORCID logo; Ghidelli-Disse, S; Lafuente-Monasterio, MJ; +43 more...Bantscheff, M; Ruecker, AORCID logo; Blagborough, AM; Zakutansky, SE; Zeeman, A; White, KL; Shackleford, DM; Mannila, J; Morizzi, J; Scheurer, C; Angulo-Barturen, I; Martínez, MSORCID logo; Ferrer, S; Sanz, LM; Gamo, FJ; Reader, J; Botha, M; Dechering, KJ; Sauerwein, RWORCID logo; Tungtaeng, A; Vanachayangkul, P; Lim, CS; Burrows, J; Witty, MJ; Marsh, KC; Bodenreider, C; Rochford, RORCID logo; Solapure, SMORCID logo; Jiménez-Díaz, MB; Wittlin, S; Charman, SA; Donini, CORCID logo; Campo, B; Birkholtz, L; Hanson, KKORCID logo; Drewes, G; Kocken, CH; Delves, MJORCID logo; Leroy, D; Fidock, DA; Waterson, D; Street, LJORCID logo; Chibale, KORCID logo and (2016) Antimalarial efficacy of MMV390048, an inhibitor of Plasmodium phosphatidylinositol 4-kinase. Science translational medicine, 9 (387). eaad9735-eaad9735. ISSN 1946-6234 DOI: 10.1126/scitranslmed.aad9735
Copy

As part of the global effort toward malaria eradication, phenotypic whole-cell screening revealed the 2-aminopyridine class of small molecules as a good starting point to develop new antimalarial drugs. Stemming from this series, we found that the derivative, MMV390048, lacked cross-resistance with current drugs used to treat malaria. This compound was efficacious against all Plasmodium life cycle stages, apart from late hypnozoites in the liver. Efficacy was shown in the humanized Plasmodium falciparum mouse model, and modest reductions in mouse-to-mouse transmission were achieved in the Plasmodium berghei mouse model. Experiments in monkeys revealed the ability of MMV390048 to be used for full chemoprotection. Although MMV390048 was not able to eliminate liver hypnozoites, it delayed relapse in a Plasmodium cynomolgi monkey model. Both genomic and chemoproteomic studies identified a kinase of the Plasmodium parasite, phosphatidylinositol 4-kinase, as the molecular target of MMV390048. The ability of MMV390048 to block all life cycle stages of the malaria parasite suggests that this compound should be further developed and may contribute to malaria control and eradication as part of a single-dose combination treatment.

Full text not available from this repository.

Atom BibTeX OpenURL ContextObject in Span Multiline CSV OpenURL ContextObject Dublin Core Dublin Core MPEG-21 DIDL Data Cite XML EndNote HTML Citation JSON MARC (ASCII) MARC (ISO 2709) METS MODS RDF+N3 RDF+N-Triples RDF+XML RIOXX2 XML Reference Manager Refer Simple Metadata ASCII Citation EP3 XML
Export

Downloads